BioSpace

Sarepta Saga Has ‘Gone on Too Long’ as Competitors Catch Up

After a series of deaths in patients taking Sarepta Therapeutics’ gene therapies, doubt has crept into investor sentiments ...
GEN

DMD Patient Dies After Treatment with Sarepta Gene Therapy

Sarepta Therapeutics said it will update its prescribing information for Elevidys ® (delandistrogene moxeparvovec-rokl) after acknowledging the sudden death of a patient with Duchenne muscular ...
Monthly Prescribing Reference

Elevidys Use for Ambulatory DMD Patients May Resume, Says FDA

Following a review of safety data in the ambulatory DMD population, the FDA had recommended the removal of the voluntary hold for these patients. The Food and Drug Administration (FDA) is allowing ...
Hosted on MSN

Sarepta Therapeutics Halts ELEVIDYS Shipments for Non-Ambulatory DMD Patients

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the best low priced pharma stocks to buy now. Towards the end of June, Sarepta Therapeutics started facing a temporary suspension of shipments for ...